Background/Aim: Sarcoidosis is a multisystem inflammatory disease characterized by the infiltration of various organs. Due to lack widely-accepted biomarker, researchers have explored alternative and previously unexplored parameters in sarcoidosis. This study aimed investigate utility markers, including systemic immune-inflammation index (SII) pan-immune-inflammation value (PIV), patients with ...

Sarcoidosis predominantly affects the lungs, intrathoracic lymph nodes, and eyes; it less frequently affects the musculoskeletal system. We herein report a case of paraneoplastic sarcoidosis in a patient presenting with multiple myeloma. The patient developed ocular sarcoidosis and showed an increased 18F-fluorodeoxyglucose uptake in the mediastinal lymph nodes and vertebral column. A lymph nod...

Sarcoidosis is a multisystem granulomatous disease that can affect any organ in the body, but most commonly the lung. Any part of the thorax may be affected by sarcoidosis, including the lung parenchyma, airways, and mediastinal and hilar lymph nodes. When the parenchyma is involved, sarcoidosis has a predilection for the bronchovascular bundles and subpleural locations. On occasion, the presen...

BACKGROUND Sarcoidosis is a multisystemic disease of unknown etiology characterized by a disproportionate Th1 granulomatous immune response in the organs involved. Plasmatic hypergammaglobulinemia and B cell accumulation in granulomatous lesions suggest the possible role of humoral immune responses in the pathogenesis of sarcoidosis. The purpose of this study is to describe B cell peripheral co...

Sarcoidosis is a multiorgan granulomatous disease in which the skin is one of the frequently involved target organs. Cutaneous involvement occurs in a third of patients with sarcoidosis and has protean manifestations. More than a century has passed since the initial description of sarcoidosis, but its cause continues to be an enigma. Recent studies have introduced several new insights into the ...

sparing in acute sarcoidosis: Results of a double, blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 17:60, 2000 67. Fazzi P: Pharmacotherapeutic management of pulmonary sarcoidosis. Am J Respir Med 2:311, 2003 68. Topalov DT, Videnovic JV, Radosavljenic TR: The long term use of methotrexate in patients with chronic disseminated sarcoidosis. Chest 118:245, 2000 69. Baugmann RP, Lynch J...

INTRODUCTION Sarcoidosis is a systemic granulomatous disease of unknown cause. The management of sarcoidosis remains problematic. Systemic and topical corticosteroids are the mainstay of therapy but may cause unacceptable side effects. Biologic therapies, such as infliximab, have recently been proposed as another treatment option for cutaneous sarcoidosis. CASE REPORT The authors describe thr...

Nodular lung disease is a rare pulmonary manifestation of sarcoidosis and resembles metastatic neoplasm disease. Nodular sarcoidosis is rare, varying from 1.6% to 4% of patients with sarcoidosis. Radiographic nodules measure from 1 to 5 cm in diameter that typically consist of coalescent granulomas. There is limited data on this form of sarcoidosis and its presentation can mimic primary or meta...

Clinical changes of lacrimal gland (LG) in sarcoidosis are studied. 33 patients (66 orbits) with verified systemic sarcoidosis were examined using digital ultrasound. Different varieties of LG structural changes in sarcoidosis are studied. Different types of LG structural changes were determined in patients with sarcoidosis defined as pseudoedematous and combined forms. Analysis of the results ...

Gastrointestinal (GI) sarcoidosis is a very rare disease, which clinically presents along with systemic disease or as an isolated finding. Gastric sarcoidosis is the most common form of GI sarcoidosis. Symptomatic gastric sarcoidosis is rare and only few case reports have been described in the literature with well-documented histological evidence of noncaseating granulomas. We present an intere...